Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
87.33
-0.26 (-0.30%)
Nov 15, 2024, 10:09 AM EST - Market open
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiology Revenue | 7.80B | 7.32B | 6.97B | 6.71B | 6.49B | 6.32B | 6.13B | 5.93B | |||||||||
| Cardiology Revenue Growth | 20.24% | 15.81% | 13.75% | 13.08% | 11.35% | 11.08% | 9.87% | 9.43% | |||||||||
| Endoscopy Revenue | 2.64B | 2.59B | 2.55B | 2.48B | 2.41B | 2.34B | 2.27B | 2.22B | |||||||||
| Endoscopy Revenue Growth | 9.68% | 10.86% | 12.35% | 11.75% | 9.06% | 7.15% | 4.33% | 3.74% | |||||||||
| Peripheral Interventions Revenue | 2.30B | 2.23B | 2.18B | 2.11B | 2.05B | 1.99B | 1.94B | 1.90B | |||||||||
| Peripheral Interventions Revenue Growth | 11.99% | 12.09% | 12.55% | 11.12% | 8.92% | 7.32% | 4.54% | 4.29% | |||||||||
| Urology Revenue | 2.10B | 2.05B | 2.01B | 1.96B | 1.91B | 1.86B | 1.83B | 1.77B | |||||||||
| Urology Revenue Growth | 9.56% | 9.87% | 9.79% | 10.77% | 10.19% | 10.43% | 11.87% | 12.00% | |||||||||
| Neuromodulation Revenue | 1.08B | 1.04B | 998.00M | 976.00M | 956.00M | 948.00M | 943.00M | 918.00M | |||||||||
| Neuromodulation Revenue Growth | 12.45% | 9.28% | 5.83% | 6.32% | 4.71% | 3.83% | 2.39% | 0.88% |
Revenue by Geography
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States Revenue | 9.53B | 9.04B | 8.68B | 8.43B | 8.20B | 8.03B | 7.86B | 7.63B | |||||||||
| United States Revenue Growth | 16.25% | 12.49% | 10.49% | 10.40% | 10.14% | 11.03% | 10.62% | 10.58% | |||||||||
| EMEA Revenue | 3.15B | 3.05B | 2.95B | 2.86B | 2.76B | 2.68B | 2.61B | 2.53B | |||||||||
| EMEA Revenue Growth | 13.90% | 13.75% | 12.70% | 13.02% | 9.17% | 5.56% | 2.99% | 0.32% | |||||||||
| APAC Revenue | 2.62B | 2.54B | 2.50B | 2.40B | 2.32B | 2.24B | 2.15B | 2.12B | |||||||||
| APAC Revenue Growth | 12.75% | 13.47% | 16.50% | 13.52% | 8.56% | 5.61% | 1.56% | 2.22% | |||||||||
| LACA Revenue | 618.00M | 605.00M | 583.00M | 560.00M | 534.00M | 507.00M | 487.00M | 468.00M | |||||||||
| LACA Revenue Growth | 15.73% | 19.33% | 19.71% | 19.66% | 17.88% | 17.09% | 19.36% | 21.24% |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative | 5.75B | 5.43B | 5.34B | 5.19B | 4.97B | 4.86B | 4.68B | 4.52B | |||||||||
| Selling, General, and Administrative Growth | 15.62% | 11.66% | 14.20% | 14.82% | 10.29% | 9.45% | 6.25% | 3.69% | |||||||||
| Research and Development | 1.52B | 1.47B | 1.44B | 1.42B | 1.38B | 1.37B | 1.34B | 1.32B | |||||||||
| Research and Development Growth | 9.91% | 7.55% | 7.68% | 6.95% | 5.26% | 6.31% | 7.54% | 9.88% | |||||||||
| Amortization | 840.00M | 843.00M | 840.00M | 829.00M | 820.00M | 814.00M | 808.00M | 803.00M | |||||||||
| Amortization Growth | 2.44% | 3.56% | 3.96% | 3.24% | 3.02% | 4.63% | 7.16% | 8.37% | |||||||||
| Restructuring Net Charges | 31.00M | 38.00M | 53.00M | 70.00M | 57.00M | 46.00M | 41.00M | 25.00M | |||||||||
| Restructuring Net Charges Growth | -45.61% | -17.39% | 29.27% | 180.00% | 35.71% | -2.13% | 5.13% | -37.50% | |||||||||
| Royalty Expense | 36.00M | 42.00M | 45.00M | 46.00M | 47.00M | 47.00M | 46.00M | 47.00M | |||||||||
| Royalty Expense Growth | -23.40% | -10.64% | -2.17% | -2.13% | 4.44% | -2.08% | -6.12% | -4.08% | |||||||||
| Contingent Consideration Net Expense | 10.00M | 45.00M | 62.00M | 57.00M | 10.00M | 18.00M | 35.00M | 35.00M | |||||||||
| Contingent Consideration Net Expense Growth | - | 150.00% | 77.14% | 62.86% | -80.00% | 350.00% | - | - | |||||||||
| Asset and Goodwill Impairment | - | 277.00M | - | - | 58.00M | 182.00M | - | - | |||||||||
| Asset and Goodwill Impairment Growth | - | 52.20% | - | - | -82.37% | -45.18% | - | - | |||||||||
| Litigation-related Net Charges | - | - | - | - | 20.00M | - | - | 173.00M | |||||||||
| Litigation-related Net Charges Growth | - | - | - | - | - | - | - | -59.77% | |||||||||
| Loss on Disposal of Assets | - | - | - | - | - | - | - | 22.00M | |||||||||
| Loss on Disposal of Assets Growth | - | - | - | - | - | - | - | 22.22% |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.